Abstract-Blacks
B
lacks have the highest prevalence of hypertension in the United States and develop hypertension at earlier ages compared with whites. 1 These differences are thought to contribute to an excess risk of hypertension-related death, heart failure, stroke, and end-stage renal disease. The mechanisms underlying racial differences in hypertension remain poorly characterized.
FGF23 (fibroblast growth factor-23) is an endocrine hormone released from the bone that acts on the kidney to stimulate phosphaturia and inhibit calcitriol synthesis.
2 FGF23 levels rise in the presence of chronic kidney disease to maintain phosphate levels; however, elevated FGF23 levels are associated with worse cardiovascular outcomes and increased mortality. [2] [3] [4] [5] Elevated FGF23 levels have also been associated with increased left ventricular mass and incident heart failure in patients without known chronic kidney disease. [6] [7] [8] FGF23 may upregulate the renin-angiotensin-aldosterone system (RAAS) by decreasing calcitriol-a potential negative regulator of the RAAS system. 9 In addition, experimental studies suggest that FGF23 may increase renal sodium uptake independent of the RAAS system leading to volume expansion and possible effects on blood pressure (BP). 10 Finally, some studies have suggested a correlation between black race and higher FGF23 levels after adjustment for demographic and clinic factors. 11 Whether FGF23 could be mechanistically involved in the risk of developing hypertension remains in question.
We sought to characterize the potential association between FGF23 and longitudinal changes in BP in a large multiethnic cohort of young and middle-aged adults free of cardiovascular disease at baseline from the CARDIA study (Coronary Artery Risk Development in Young Adults). We hypothesized that higher FGF23 levels would be independently associated with greater increases in BP over time and a higher risk of incident hypertension in blacks compared with whites.
Methods
Data from the CARDIA study are not publicly available. More information about CARDIA can be found at http://www.cardia. dopm.uab.edu/.
Source Population
The CARDIA study is a longitudinal cohort study that enrolled 5115 healthy young black and white adults aged 18 to 30 years from 4 field centers (Birmingham, AL; Minneapolis, MN; Chicago, IL; Oakland, CA) from 1985 to 1986. The study was designed to investigate biological and behavioral factors contributing to the development of cardiovascular disease in young adults. Full details about the design of the CARDIA study have been published previously. 12 To date, there have been 9 total examinations (baseline, years 2 [1987] [1988] , 5 [1990-1991] 
Study Sample
FGF23 measures were first available at the year 20 examination. Of the 5115 CARDIA participants at baseline, 3547 participated in the year 20 examination. Three thousand four hundred two (95.9%) had adequate samples for FGF23 measurement at the year 20 examination. We excluded participants with prevalent hypertension, defined as taking antihypertensive medication, having a systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg at the time of year 20 visit (n=1269). We also excluded participants with cardiovascular disease, defined as previous heart failure, myocardial infarction, coronary revascularization, angina, stroke, transient ischemic attack, or peripheral vascular disease (n=251). Finally, we excluded patients with no follow-up BP values (n=124). The final study sample was composed of 1758 individuals.
Ascertainment of Incident Hypertension
BP was measured at each examination by trained CARDIA staff. For the year 20, 25, and 30 exams, BP was measured using Omron HEM907XL sphygmomanometers. Per CARDIA standardized protocol, participants had 3 BP readings taken after sitting in a quiet room for 5 minutes. The second and third readings were then averaged. Incident hypertension was defined as any of the following at the year 25 or year 30 examination: (1) report of antihypertensive medication use and (2) systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg per most recent 2017 guidelines.
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Measurement of FGF23
CARDIA study personnel collected blood samples after a fasting period, and both serum and plasma samples were frozen to −70°C for long-term storage based on a standardized protocol. For FGF23 analyses, samples were shipped to the University of Miami Biomarker and Immunoassay Laboratory. We measured plasma cFGF23 (C-terminal FGF23) using a second-generation ELISA, which detects epitopes within the carboxyl-terminal portion of FGF23 (Immutopics, Inc, Athens, OH; intra-assay coefficient of variation <3%). We analyzed 10% of the samples in duplicate for quality control purposes. We included a low-and high-value internal control sample for each run of the assay. Because the assays were performed in 2 separate shipments, these procedures were done for each independently. For the first shipment of samples, the interassay and intra-assay variabilities were 3.9% and 4.1% for the low-value control and 2.3% and 4.1% for the high-value control, respectively. For the second shipment of samples, the interassay and intra-assay variabilities were 4.3% and 4.8% for the low-value control and 2.8% and 4.0% for the high-value control, respectively. We also measured intact FGF23 (iFGF23) using a second-generation Immutopics ELISA-based assay, which detects epitopes within the amino and carboxyl portions of FGF23. We performed similar quality control testing for this assay. In vivo, a portion of synthesized FGF23 is cleaved into separate protein fragments. The C-terminal assay detects these fragments along with the full-length intact protein, whereas the intact assay detects only the full-length protein.
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Other Study Variables
Standardized questionnaires were administered at each CARDIA examination and according to published protocols. 12 Sex, race, education level, alcohol use, and smoking status were self-reported by participants. Body mass index (BMI) was calculated from standardized height and weight measurements. Physical activity was determined through a questionnaire and reported as exercise units. 15, 16 Diabetes mellitus was defined as a fasting glucose ≥126 mg/dL or on a diabetic medication. Estimated glomerular filtration rate (eGFR) was calculated based on the CKD-EPI equation (Chronic Kidney Disease Epidemiology Collaboration).
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Statistical Analysis
Baseline characteristics of the study population were summarized by FGF23 quartiles. Continuous variables were expressed as means and categorical variables as proportions. We used 1-way ANOVA and the Kruskal-Wallis test to compare normally and non-normally distributed continuous variables, respectively. We used the χ 2 test to compare categorical variables. To investigate the association of cFGF23 with systolic and diastolic BP over time, we constructed linear mixed models and generated least squares means estimates of systolic and diastolic BP at each of the 3 exams within each of the cFGF23 quartiles from fully adjusted models. We constructed 2 nested multivariable models. Model 1 adjusted for age, sex, race, education, and study center. Model 2 additionally adjusted for BMI, physical activity, 15, 16 smoking status, triglyceride/high-density lipoprotein ratio, eGFR, and urine albumin-to-creatinine ratio. All covariables were included in the models as fixed effects. To account for the presence of antihypertensive therapy at the follow-up visits, we added 10 mm Hg to the systolic and 5 mm Hg to the diastolic BP of participants taking antihypertensive therapy. [18] [19] [20] Finally, because unlike systolic BP, diastolic BP tends to decrease with advanced age, we repeated analyses using pulse pressure (pulse pressure=systolic BP−diastolic BP).
To investigate the association of cFGF23 at baseline (year 20) with incident hypertension during the 2 follow-up visits (years 25 and 30), we used a modified Poisson regression approach with robust error variance to estimate the relative risk of incident hypertension for each of the higher FGF23 quartiles compared with the lowest quartile. 21 Multivariable models were adjusted for the same variables as aforementioned. To evaluate whether any association between FGF23 and incident hypertension was modified by race, in fully adjusted models, we tested for interactions between FGF23 and race. We also tested for interactions between FGF23 and sex. Because chronic kidney disease is strongly associated with both higher FGF23 and hypertension, in sensitivity analyses, we excluded individuals with chronic kidney disease at baseline, which we defined as an eGFR <60 mL/min per 1.72 m 2 or a urine albumin-to-creatinine ratio ≥30 mg/g. Finally, we repeated all analyses using iFGF23 measurements instead of cFGF23. A P value of <0.05 was considered statistically significant. We performed all statistical analyses using SAS software, version 9.4 (SAS Institute, Inc, Cary, NC).
Results
The mean age of the cohort was ≈45 years (45.0±3.7); 57.8% of the cohort was female and 36.9% black. The mean eGFR was 97.7±16.0 mL/min per 1.72 m 2 , and mean systolic BP was 109.4±9.3 mm Hg. Few participants had an eGFR <60 mL/ min per 1.72 m 2 (0.1%). Baseline demographics categorized by cFGF23 quartile are presented in Table 1 . The mean age was similar across cFGF23 quartiles. There were higher proportions of female and diabetic participants along with current smokers in the higher cFGF23 quartiles. BMI was also greater in higher cFGF23 quartiles. Baseline systolic and diastolic BPs were similar across cFGF23 quartiles. Participants in the highest cFGF23 quartile had higher median urine albumin-tocreatinine ratio levels, as well as having the highest proportion of participants with a urine albumin-to-creatinine ratio ≥30 mg/g. Mean eGFR was similar across cFGF23 quartiles at baseline (Table 1 ) and in years 25 and 30 (Table S1 in the online-only Data Supplement).
Association of FGF23 and BP Levels Over Time
In fully adjusted mixed models (including all model 2 covariables), higher cFGF23 quartiles were associated with increasing systolic BP over time (Figure 1 Increases in diastolic BP were also greater in the highest cFGF23 quartile relative to the lowest quartile during the year 20 to 25 time period (Figure 2 : +1.6 mm Hg for quartile 4 relative to quartile 1; P=0.0024). There were no statistically significant differences in the change in diastolic BP for quartile 3 relative to quartile 1 between years 20 and 25 but a significant difference for quartile 2 relative to quartile 1. Between years 25 and 30, diastolic BP slopes in the top 3 quartiles were similar to the lowest quartile. However, during this year 25 to 30 time period, there was a significantly greater increase in pulse pressure in the highest cFGF23 quartile relative to the lowest quartile ( Figure S1 ).
Association of FGF23 With Incident Hypertension
During follow-up, 35.2% (618) of participants developed hypertension. The crude 10-year incidence of hypertension by cFGF23 quartile for the cohort overall and stratified by race and sex is presented in Figure 3 . Hypertension developed in more participants in higher cFGF23 quartiles (P for trend, Values are expressed as n (%), mean (SD), and median (25th-75th percentile). P values are for trend. ACR indicates albumin-to-creatinine ratio; BMI, body mass index; cFGF23, C-terminal fibroblast growth factor-23; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; and SBP, systolic blood pressure.
*Total physical activity score in exercise units.
<0.0001). Blacks had a higher overall incidence of hypertension (47.7%; 309 of 648) compared with whites (27.8%; 309 of 1110). When stratified by race, greater rates of incident hypertension continued to be present in higher FGF23 quartiles. In fully adjusted analyses incorporating BMI, smoking status, and markers of renal function, cFGF23 levels in the highest quartile were associated with a 45% greater risk of developing hypertension compared with the lowest quartile (Table 2 ; relative risk, 1.45 [1.18-1.77]). There were also statistically significant associations with incident hypertension for the middle 2 FGF23 quartiles compared with the lowest quartile of FGF23 in fully adjusted models. The risk of developing incident hypertension was greater in the highest quartiles (Table 2 : P for trend, 0.0002).
Although blacks had a higher incidence of hypertension than whites, there was no significant interaction by race Analyses repeated with iFGF23 did not demonstrate a similar independent association with incident hypertension (Table S2) or BP over time.
Discussion
In this study, we investigated whether FGF23 was associated with changes in BP and incident hypertension in a large multiethnic population of young and middle-aged adults. We demonstrated that higher FGF23 levels were associated with increasing systolic and diastolic BP during follow-up, despite similar baseline readings and that FGF23 was also associated with incident hypertension even after adjustment for potential confoundersincluding BMI, smoking status, and markers of renal function. Although there were more black and female participants in the highest FGF23 quartile, the association of FGF23 with incident hypertension did not vary based on these demographic characteristics. Additionally, the association did not vary based on the presence of underlying kidney disease, which was only present in a small percentage of the study population.
Our findings of an association between FGF23 and rising systolic and diastolic BP over time lend support to experimental evidence that suggests there are mechanisms by which FGF23 could affect BP. Experimental data suggest that in chronic kidney disease, increased FGF23 contributes to RAAS activation by decreasing calcitriol synthesis, which in turn may lead to increased renin production, 9 in addition to other potential mechanisms by which FGF23 may modulate the RAAS system, such as suppression of angiotensin-converting enzyme 2. [22] [23] [24] Experimental data also suggest that FGF23 may increase renal sodium uptake independent of the RAAS system. 10 A previous study examining a possible association of FGF23 with incident hypertension in a primarily white population of older adults suggested that individuals in the highest FGF23 decile of values had a modestly increased risk of developing hypertension. 25 Our study extends prior analyses in 2 significant ways. By the time US adults reach ages 55 to 64 years, the prevalence of hypertension already exceeds 50%. 1 Given that the incidence of hypertension and other cardiovascular disease increases with age, we focused on a younger population that was free of cardiovascular disease. Second, we investigated the association of FGF23 with changes in both systolic and diastolic BP measurements in a longitudinal fashion rather than only examining incident hypertension as an outcome alone. It is notable that even though our population would overall be expected to have less comorbid conditions than older populations, we demonstrate a significant association between higher FGF23 and incident hypertension risk not explained by other known risk factors for cardiovascular disease. Our findings further suggest that FGF23 may be an independent marker of risk of developing hypertension.
Our findings also have other potentially significant implications. Increasing BP levels not meeting criteria for hypertension are nonetheless associated with worse cardiovascular outcomes. 1, 26 In addition, there is evidence to suggest that antecedent BP contributes significantly to future cardiovascular risk even when taking into account current BP and hypertensive status. 27, 28 Small numeric differences in BP can have significant meaning for outcomes on a population level. Thus, the differential rises in BP associated with higher FGF23 levels may have potential implications in and of themselves for future cardiovascular risk regardless of the presence of clinically diagnosed hypertension.
Strengths of our study include use of a large, well-characterized prospective cohort of black and white individuals. Nevertheless, this study has important limitations. We did not measure FGF23 levels at the baseline (first) examination, so we could not study incident hypertension at earlier ages. Other racial/ethnic groups were not part of the CARDIA cohort. Thus, our findings may not be generalizable to all racial/ethnic groups or age groups. We adjusted for important covariables, including BMI, smoking, and markers of renal function. Although we think this would account for most confounding, we did not have other metabolic correlates, such as serum renin, aldosterone, or urine sodium levels. Thus, residual confounding from these and other factors cannot be excluded. In addition, not having such indices available limited our evaluation of mechanisms that could help explain an association between FGF23 and BP. Such mechanistic insights will be important to further characterize this association and in turn might have implications for potential future therapeutic interventions. Studies of pharmacological interventions to reduce FGF23, such as phosphate binders and calcimimetics, have primarily been in the setting of chronic kidney disease. 29 Monoclonal antibodies inhibiting FGF23 activity are also under investigation, but studies have been primarily experimental with only limited clinical data. 30 Whether any pharmacological interventions would be safe and effective in the setting of increased FGF23 and elevated BP is unknown and beyond the scope of this study. Finally, we did not find an association between iFGF23 and incident hypertension. This finding illustrates that the choice of assay may be important when investigating possible associations of FGF23 with cardiovascular disease and other outcomes. Previous data have suggested that cFGF23 has less intraindividual variation than iFGF23, 14 yet associations between iFGF23 and cardiovascular disease have nonetheless been found previously. 7, 25 Our study is the first to evaluate the association of both an intact and C-terminal assay for incident hypertension. Further study is needed to clarify the importance of type of assay when investigating possible associations with cardiovascular risk.
In conclusion, higher FGF23 levels are independently associated with rising BP over time and an increased risk of incident hypertension in young and middle-aged adults but do not explain the disparate burden of hypertension in blacks. Further study is necessary to elucidate the mechanisms by which higher FGF23 may contribute to unfavorable BP trajectories.
Perspectives
Hypertension is a well-known risk factor for cardiovascular disease that is prevalent around the world. In this study, we demonstrated that higher FGF23 levels are independently associated with both increasing BP over time and incident hypertension in a population of young and middle-aged adults without a high burden of chronic kidney disease and other significant comorbidities. Our findings suggest that FGF23 could have a clinical role as a novel marker in helping to identify individuals at higher risk of developing hypertension, beyond known risk factors. Defining the potential mechanisms by which FGF23 contributes to higher BP may also have future implications for determining therapeutic options. Additional study of FGF23 in other young adult populations and of the mechanisms by which it may increase BP is necessary to further explore these potentially clinically important hypotheses.
